1 Intravenous administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 150pg kg-1) into conscious sham-operated rats caused significant increases in basal glycaemia with minor changes in basal insulinaemia. Glucose-stimulated (intravenous glucose tolerance test) plasma insulin levels were significantly inhibited in 8-OH-DPAT-treated sham-operated animals. These metabolic changes were associated with significant and sustained falls in blood pressure (BP) and heart rate (HR) preceded by transient (< 5 min) increases only in BP.
Introduction
Methods 5-HydroxytryptaminelA (5-HT1A) receptor agonists such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan decrease blood pressure (BP) and heart rate (HR) in many species through an interaction with central 5-HTIA-receptors Ramage & Fozard, 1987; Doods et al., 1988 ; for review see Mir & Fozard, 1990) . These actions are associated with an increase in vagal tone and sympathoinhibition (Ramage & Fozard, 1987; Ramage et al., 1988) . 8-OH-DPAT has been shown also to act on the endocrine system. For example, 8-OH-DPAT, through activation of 5-HTlA-receptors, decreases plasma insulin and increases basal plasma glucose levels in several rat strains, via a central mechanism of action (Chaouloff & Jeanrenaud, 1987 Laude et al., 1990) . 5-HTlA-receptor agonists enhance plasma levels of corticosterone (Koenig et al., 1987; Aulakh et al., 1988; Chaouloff et al., 1990c; and catecholamines (Badgy et al., 1989; Chaouloff et al., 1990a; Laude et al., 1990) . We have shown previously that despite the fact that the effects of 8-OH-DPAT on glucose and insulin are centrally mediated, they are dependent upon the adrenal glands being intact . Similarly, the initial short-lasting pressor effect of 8-OH-DPAT (Gradin et al., 1985; Bagdy et al., 1989) is also dependent on intact adrenal glands . Both parts of the adrenal gland (cortex and medulla) can participate in glucose metabolism, through their respective secretory products (corticosteroids and catecholamines). The objective of the present study was to investigate the importance of the medulla versus the cortex of the adrenal gland in the mediation of the metabolic (hyperglycaemia and inhibition of insulin release during a glucose tolerance test) and pressor effects of 8-OH-DPAT by using adrenodemedullated and sham-operated conscious Sprague-Dawley rats.
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Animals
Adrenodemedullated and sham-operated Sprague-Dawley rats (300-380 g) were supplied by IFFA-CREDO (Les Oncins, France). They had free access to food and were given a solution of 1% saccharose and 0.9% NaCl to drink during the course of the study. Animals were maintained on a constant 12 h light cycle. Animals were used about 2 to 3 weeks after adrenodemedullation. Successful adrenodemedullation was assessed by measuring the adrenal catecholamines at the end of the experiments.
Intravenous glucose tolerance test (IVGTT) and cardiovascular recordings in conscious animals
Experiments were conducted with minor modification of the procedures described in detail previously . Briefly, catheters were implanted under sodium hexobarbitone (NA-Evipan) anaesthesia (160mgkg-1 i.p.) in the femoral artery and vein. Cannulae were passed subcutaneously and exteriorized at the back of the neck. At the end of surgery cannulae were filled with heparinized saline to avoid blood clotting. Experiments were performed at least three days after surgery. BP and HR were recorded continuously from the arterial cannula as described in detail previously . After a stabilization period of about 1 h an arterial blood sample (200,ul) (Chaouloff & Jeanrenaud, 1987 ; therefore, this dose was used in the present study. Glucose (0.5gkg-1 in 0.5ml water) was ,'-. Macmillan Press Ltd, 1991 then injected i.v. and further blood samples withdrawn after 1, 3, 6, 12, 24, and 48 (10,ul) of the plasma were used to determine glucose concentrations by use of an automatic glucose analyser (Ektachem, Kodak). The remainder of the plasma was stored at -200C for subsequent insulin and corticosterone assay. Insulin was determined, by use of the radioimmunoassays described by Hales & Randle (1963) . Corticosterone was determined by a modification of a radioimmunoassay described by Abraham (1977) . Briefly, 2Opl of plasma were diluted 500 fold with a phosphate buffer containing 0.2% gelatin. Diluted samples (500,u1) and standards were heated at 980C for 10 min in order to denature corticosterone-binding rat plasma proteins. After the samples had cooled to room temperature, [3H]-corticosterone (100pl, about 10,000c.p.m.) and anti-corticosterone antibody (100,p1)
were successively added. The antibody concentration was selected to produce 50% of maximal binding. After an incubation at 40C for 2h, separation of free corticosterone from antibody bound corticosterone was achieved by use of 200,pl of coated charcoal suspension (0.6%). Following centrifugation (2500 r.p.m. for 15min), supernatants containing bound corticosterone were collected and counted in a fl-counter.
Adrenal tissue catecholamine measurements
At the end of the experiment, adrenal glands were removed and stored at -180°C and subsequently, tissue adrenaline, noradrenaline and dopamine concentrations were measured by reverse phase high performance liquid chromatography and electrochemical detection according to the method of Kempf & Mandel (1981) .
Drugs and solutions (±)-8-OH-DPAT hydrogen bromide (Research Biochemicals
Inc.) was dissolved in 0.9% (w/v) NaCl for in vivo experiments. (Le Floch et al., 1990) .
Results
Conscious sham-adrenodemedullated rats In sham-operated animals, 8-OH-DPAT (150pgkg-' i.v.) significantly increased basal plasma glucose concentrations after 15min (Figure la) , without a change in basal plasma insulin (Figure lb) . Following an intravenous injection of glucose (IVGTT) to 8-OH-DPAT-treated animals, the stimulated plasma insulin levels were reduced in association with an increase in plasma glucose levels. When both the first 15min of 8-OH-DPAT-induced hyperglycaemia and the IVGTT were taken into account (0-63min), a significant decrease in AUC for plasma insulin was found in the 8-OH-DPATtreated group whereas the plasma glucose was increased by 41%, although the increase did not reach statistical significance due to the variation (Table 1) . As expected, 8-OH-DPAT at the same dose produced sustained falls in both BP and HR which were preceded by transient (< 5 min) increases in BP (Figure ic and d) . Control saline injections did not produce any change of the above parameters (data not shown).
Conscious adrenodemedullated rats
In contrast to sham-operated animals, 8-OH-DPAT did not modify plasma levels of glucose or insulin either under basal 
Discussion
The major conclusion that emerges from this study is that the hyperglycaemic response of 8-OH-DPAT, its inhibitory action on glucose-stimulated insulin release and the transient vasoconstrictor effect are mediated by the medulla of the adrenal gland. The extent of adrenodemedullation was assessed by the determination of catecholamines in the adrenal gland tissue. A 95% reduction in noradrenaline, adrenaline and dopamine indicates nearly a complete adrenodemedullation and suggests a role for the medullary catecholamines in the metabolic and vasoconstrictor effects of 8-OH-DPAT. The fact that 8-OH-DPAT Chaouloff et al., 1990a) increases plasma adrenaline and that selective a2-and #2-adrenoceptor antagonists (Chaouloff & Jeanrenaud, 1987; Chaouloff et al., 1990a ) suppress 8-OH-DPAT-mediated hyperglycaemia supports the involvement of adrenal catecholamines in the metabolic effects of 8-OH-DPAT. Moreover, the fact that the plasma glucose levels are significantly increased in shamoperated rats following 8-OH-DPAT administration, without significant increase in corticosterone, suggests that the hyperglycaemia is not a consequence of corticosterone release in the present study. The adrenaline-releasing effects of 8-OH-DPAT are antagonized by the mixed 5-HTlA-fi-adrenoceptor antagonist, (-)-pindolol, but not by selective /l1-or f2-adrenoceptor antagonists (Chaouloff et al., 1990a) . Moreover, adrenaline release and hyperglycaemia is induced by several other selective 5-HTlA-receptor agonists such as buspirone, ipsapirone (Chaouloff et al., 1990b) and flesinoxan (Mir et al., unpublished observations) , thus implicating a key role for the 5-HTlA-receptors in the regulation of adrenaline release and glucose metabolism. 8-OH-DPAT has been shown to increase plasma levels of corticosterone in the rat (Koenig et al., 1987; Aulakh et al., 1988; Chaouloff et al., 1990c) , which can be considered as another potential contributory factor to the 8-OH-DPATinduced hyperglycaemia. However, the nature and extent of the involvement of corticosterone in this respect is not clearly established (Chaouloff et al., 1990c) . In the present study no significant stimulation of corticosterone levels was observed 15min following 8-OH-DPAT administration. This lack of stimulation appears unlikely to be due to a non-functional cortex since in both adrenodemedullated and sham-operated animals corticosterone production was present.
With regard to the cardiovascular effects of 8-OH-DPAT, the transient vasoconstriction in response to 8-OH-DPAT, preceding the falls in BP and HR is abolished in adrenodemedullated animals. This finding, confirms a previous observation in adrenalectomized animals , and together with the observations that 8-OH-DPAT increases plasma catecholamine levels Chaouloff et al., 1990a) and that the pressor response is attenuated by prazosin (Gradin et al., 1985) , supports the involvement of catecholamines in the pressor response to 8-OH-DPAT. 8-OH-DPAT also produces a small transient pressor response in pithed rats ). This action is unlikely to be due to catecholamine release, since Chaouloff et al. (1990d) have shown that penthobarbitone anaesthesia completely suppresses the adrenaline release which normally occurs in conscious animals. Rather, a direct vascular action in response to a bolus intravenous injection is a possible mechanism. The fact that 8-OH-DPAT produces similar hypotensive and bradycardic effects in sham and adrenodemedullated rats confirms previous observations in adrenalectomized rats , and lends, further support to the difference in mechanisms in the hypotensive and bradycardic effects vis-a-vis the vasoconstrictor and metabolic effects. Paradoxically, the metabolic changes (hyperglycaemia and hypoinsulinaemia) would generally be expected to arise from sympathoexcitation and/or a decrease in vagal tone (Ahren et al., 1986) , which is the opposite of what has been established to be the basis of the 8-OH-DPAT effects on the cardiovascular system (see Introduction). Thus it appears that 8-OH-DPAT exerts a differential action on the autonomic nervous system with respect to its metabolic and major cardiovascular effects (hypotension and bradycardia). In Figure 2 , a tentative model to explain the mechanisms of 5-HTlA-mediated metabolic and cardiovascular effects is illustrated. 5-HT and 8-OH-DPAT stimulate the release of corticotrophin-releasing factor (CRF) (Jones et al., 1976; Calogero et al., 1989) . In addition to its well known ACTHreleasing activity, CRF is also known to stimulate directly sympathetic tone to the adrenal medulla via a central site of action (for review see Fisher, 1989) , manifested by increases in efferent adrenal nerve activity, plasma adrenaline concentrations and an increase in BP (Brown & Fisher, 1983; Brown et al., 1985) . Hyperglycaemia has also been observed after intracerebroventricular injections of CRF in the rat and the dog (Brown et al., 1982 glucose (Chaouloff et al., 1990c) would also be consistent with a centrally mediated sympatho-adrenal stimulation. Therefore, the possibility that 8-OH-DPAT-mediated catecholamine release, which would result in hyperglycaemia and hypoinsulinaemia, is triggered by CRF deserves further attention.
Taken together, these data strongly suggest that 8-OH-DPAT exerts its metabolic and transient pressor effect primarily via an action on the adrenal medulla. The data further confirm the differences in the mechanisms underlying the hypotensive and bradycardic actions of 8-OH-DPAT vis-a-vis the effects on glucose homeostasis. The major cardiovascular effects (hypotension and bradycardia) of 5-HTlA agonists may thus be regarded as being mediated purely by neuronal pathways whereas the metabolic effects involve mixed neuronal and humoral mechanisms (see Figure 2) .
